Meet GCAL® in September: Circulating calprotectin for routine rheumatology

Learn how circulating calprotectin supports better patient care in IRDs 

Meet us at three key European congresses this September

This September, Gentian Diagnostics will be showcasing GCAL^® – our innovative assay for circulating calprotectin – at three of Europe’s leading rheumatology congresses:

• 40th Scandinavian Congress of Rheumatology (Malmø, Sweden)

• Deutscher Rheumatologiekongress (Wiesbaden, Germany)

• PReS 2025 (Helsinki, Finland)

If you are attending any of these congresses or have contacts who would benefit from learning more, we encourage you to connect with us during the events.

The expanding role of serum and plasma calprotectin in IRD

Serum and plasma calprotectin measurement is emerging as a valuable biomarker for systemic inflammation and in inflammatory rheumatic diseases (IRD). At these three congresses, we will present new clinical evidence, share insights from recent studies, and discuss how calprotectin can supports both adult and paediatric care. 

Visit our booths or book a meeting in advance to discuss the growing clinical relevance of circulating calprotectin and the important role GCAL^® plays in improving the assessment of inflammatory status and patient care.

40th Scandinavian Congress of Rheumatology 2025

The 40th Scandinavian Congress of Rheumatology “Reumadagarna” will be held in Malmö, Sweden, from 3-6 September 2025. The congress gathers experts from the Nordic region to share advances in patient care and research. Gentian will present updates on how GCAL^® is supporting a more precise evaluation of disease activity in IRDs.

Visit our team at stand #24 to learn more!

Deutscher Rheumatologiekongress 2025

From September 17–20^th in Wiesbaden, Germany’s premier rheumatology meeting, the Deutscher Rheumatologiekongress, will provide a leading platform for scientific exchange on new diagnostic approaches and treatment strategies.

Gentian looks forward to meeting clinicians and partners to discuss the potential of circulating calprotectin as a valuable clinical biomarker in routine IRD management, and the implementation of GCAL^® in routine use across Europe.

PReS 2025 – Paediatric Rheumatology European Society Congress

The Paediatric Rheumatology European Society (PReS) 2025 is a central meeting for paediatric rheumatology specialists, with a strong focus on improving outcomes for children and adolescents living with IRDs. At this year’s PReS you will meet the GCAL^® team at booth #4

Together with academic collaborators from the University of Zagreb, Gentian will showcase research showing that circulating calprotectin can reliably detect systemic inflammation and assess disease activity in paediatric patients.

Visit our team at booth #4 to learn more!

GCAL® - Plasma & serum calprotectin:
Easy implementation in routine

The GCAL^® assay is designed for the quantitative determination of calprotectin in plasma and serum, intended as an aid in detection and assessment of inflammation and inflammatory response to infections. As the first turbidimetric assay available since 2019, GCAL^® offers distinct advantages:

• Advanced technology: PETIA assay on clinical chemistry platforms using avian antibodies, which minimises interference from rheumatoid factor and HAMA antibodies
• Versatility: Compatible with a wide range of automated clinical chemistry analysers
• Regulatory compliance: CE-marked in compliance with IVDR 2017/746 (CE 0123) and registered in multiple regions*
• Ready-to-use format: Complete kit components - including dedicated calibrators and controls - are available in two sizes to meet the needs of both small and high-volume clinics and laboratories
  
  

Get in touch with us

Explore GCAL^® in your clinical practice or laboratory - fill out the form or send an email to marketing@gentian.com for more information about the product, validation and prices.

* This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.